Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

Azacitidine is the first drug to demonstrate a survival benefit for patients with MDS. However, only half of patients respond and almost all patients eventually relapse. Limited and conflicting data are available on predictive factors influencing response. We analyzed 128 patients from two instituti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuendgen, Andrea, Müller-Thomas, Catharina, Lauseker, Michael, Haferlach, Torsten, Urbaniak, Petra, Schroeder, Thomas, Brings, Carolin, Wulfert, Michael, Meggendorfer, Manja, Hildebrandt, Barbara, Betz, Beate, Royer-Pokora, Brigitte, Gattermann, Norbert, Haas, Rainer, Germing, Ulrich, Götze, Katharina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021252/
https://www.ncbi.nlm.nih.gov/pubmed/29963245
http://dx.doi.org/10.18632/oncotarget.25328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021252/
https://www.ncbi.nlm.nih.gov/pubmed/29963245
http://dx.doi.org/10.18632/oncotarget.25328

Ejemplares similares